A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

Prior treatment

• Concomitant disease that could interfere with treatment or conduct of study
• Use of any treatment within the 2 weeks or within 5 half-lives prior to first dosing (whichever is longer)
  • CHB participants:
• History of or currently receiving any systemic anti-neoplastic or immune-modulatory treatment within the 8 weeks prior to the first dosing or the expectation that such treatment will be needed at any time during the study.

Other illness

• History of any clinically significant disease
• Evidence of liver cirrhosis or decompensated liver disease
• History or evidence of a medical condition associated with chronic liver disease other than HBV infection, or clinically significant and not adequately controlled non-hepatic disease

Other

• Healthy volunteers:
• History or suspicion of hepatocellular carcinoma (HCC)

• Healthy volunteers:
• Healthy participants
• Body mass index (BMI) between 18 and 32 kg/m\^2
  • CHB participants:
• CHB infection (HBsAg-positive for >/= 6 months)
• On NUC (ETV, TAF, or TDF) monotherapy for >/= 12 months
• Liver biopsy, FibroScan, or equivalent test within the past 6 months demonstrating liver disease consistent with chronic HBV infection without evidence of bridging fibrosis or cirrhosis
• BMI between 18 and 32 kg/m\^2